This program provides retina specialists and other ophthalmologists caring for patients with neovascular AMD and DME with a comprehensive overview of sustained-release therapies for retinal diseases. Participants will appraise the latest clinical data on the safety and efficacy of sustained delivery platforms, including the Port Delivery System (PDS) with ranibizumab, and emerging options like tyrosine kinase inhibitors and gene therapies. The program will detail the technical considerations for optimizing the safety and efficacy of sustained delivery, with a specific focus on the PDS surgical implantation and refill-exchange procedures. Through case-based discussions, learners will evaluate patient-specific characteristics to determine the appropriate implementation of sustained delivery platforms, considering factors such as treatment history, ocular comorbidities, and individual patient needs to select optimal treatment approaches for neovascular AMD and DME.

Target Audience:

Retina specialists and other ophthalmologists caring for patients with neovascular AMD and DME.

Learning Objectives:

• Appraise the latest data regarding the safety and efficacy of sustained delivery platforms for retinal diseases
• Identify technical considerations to optimize the safety and efficacy of sustained delivery therapies for retinal diseases
• Evaluate patient-specific characteristics when considering implementation of sustained delivery platforms for retinal diseases